Prior use of therapeutic anticoagulation does not protect against COVID‐19 related clinical outcomes in hospitalized patients: a propensity score‐matched cohort …
JP Spiegelenberg, MMHJ van Gelder… - British Journal of …, 2021 - Wiley Online Library
The hypercoagulable state observed in COVID‐19 could be responsible for morbidity and
mortality. In this retrospective study we investigated whether therapeutic anticoagulation …
mortality. In this retrospective study we investigated whether therapeutic anticoagulation …
Trends in venous thromboembolism anticoagulation in patients hospitalized with COVID-19
VM Vaughn, M Yost, C Abshire, SA Flanders… - JAMA network …, 2021 - jamanetwork.com
Importance Venous thromboembolism (VTE) is a common complication of COVID-19. It is
not well understood how hospitals have managed VTE prevention and the effect of …
not well understood how hospitals have managed VTE prevention and the effect of …
Therapeutic anticoagulation is associated with decreased mortality in mechanically ventilated COVID-19 patients
MA Trinh, DR Chang, US Govindarajulu, E Kane… - MedRxiv, 2020 - medrxiv.org
Objective To evaluate differences in morbidity and mortality among mechanically ventilated
patients with COVID-19 treated with therapeutic versus prophylactic anticoagulation …
patients with COVID-19 treated with therapeutic versus prophylactic anticoagulation …
Outpatient and inpatient anticoagulation therapy and the risk for hospital admission and death among COVID-19 patients
Abstract Background Coronavirus disease 2019 (COVID-19) is associated with a
hypercoagulable state. Limited data exist informing the relationship between anticoagulation …
hypercoagulable state. Limited data exist informing the relationship between anticoagulation …
Efficacy and safety of heparin full-dose anticoagulation in hospitalized non-critically ill COVID-19 patients: a meta-analysis of multicenter randomized controlled trials
E Pilia, A Belletti, S Fresilli, G Finco… - Journal of Thrombosis and …, 2022 - Springer
Arterial and venous thrombotic events in COVID-19 cause significant morbidity and mortality
among patients. Although international guidelines agree on the need for anticoagulation, it …
among patients. Although international guidelines agree on the need for anticoagulation, it …
Thromboembolic prevention and anticoagulant therapy during the COVID-19 pandemic: updated clinical guidance from the anticoagulation forum
GD Barnes, A Burnett, A Allen, J Ansell… - Journal of thrombosis …, 2022 - Springer
Thromboembolism is a common and deadly consequence of COVID-19 infection for
hospitalized patients. Based on clinical evidence pre-dating the COVID-19 pandemic and …
hospitalized patients. Based on clinical evidence pre-dating the COVID-19 pandemic and …
[HTML][HTML] The hazard of (sub) therapeutic doses of anticoagulants in non‐critically ill patients with Covid‐19: The Padua province experience
R Pesavento, D Ceccato, G Pasquetto… - Journal of Thrombosis …, 2020 - Elsevier
Abstract Background Coronavirus Disease 2019 (COVID‐19) is responsible for a worldwide
pandemic, with a high rate of morbidity and mortality. The increasing evidence of an …
pandemic, with a high rate of morbidity and mortality. The increasing evidence of an …
Anticoagulant treatment in COVID-19: a narrative review
V Carfora, G Spiniello, R Ricciolino, M Di Mauro… - Journal of thrombosis …, 2021 - Springer
Abstract The actual Coronavirus Disease (COVID 19) pandemic is due to Severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), a member of the coronavirus family …
respiratory syndrome coronavirus 2 (SARS-CoV-2), a member of the coronavirus family …
[HTML][HTML] Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID‐19: a multi‐center, open‐label, randomized controlled trial
US Perepu, I Chambers, A Wahab, P Ten Eyck… - Journal of Thrombosis …, 2021 - Elsevier
Abstract Background Coronavirus disease 2019 (COVID‐19) is associated with
coagulopathy but the optimal prophylactic anticoagulation therapy remains uncertain and …
coagulopathy but the optimal prophylactic anticoagulation therapy remains uncertain and …
[HTML][HTML] Risk factors for systemic and venous thromboembolism, mortality and bleeding risks in 1125 patients with COVID-19: relationship with anticoagulation status
W Li, Z Xu, H Xiang, C Zhang, Y Guo, J Xiong - Aging (Albany NY), 2021 - ncbi.nlm.nih.gov
Aim: Coronavirus disease 2019 (COVID-19) has been associated with increased mortality
and morbidity from thromboembolism, especially venous thromboembolism. There are more …
and morbidity from thromboembolism, especially venous thromboembolism. There are more …